NCT00163384 Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136) Status COMPLETED Phase PHASE3
NCT00163371 Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) Status COMPLETED Phase PHASE3
NCT00163358 Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132) Status COMPLETED Phase PHASE3
NCT00163345 Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131) Status COMPLETED Phase PHASE3
NCT00163332 Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129) Status COMPLETED Phase PHASE3
NCT00163319 Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101) Status COMPLETED Phase PHASE3
NCT00163293 Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) Status COMPLETED Phase PHASE3
NCT00162305 A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Status COMPLETED Phase PHASE2
NCT00157768 IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction Status COMPLETED Phase PHASE4
NCT00156715 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Status COMPLETED Phase PHASE4
NCT00139074 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Status TERMINATED Phase PHASE4
NCT00138125 Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer Status TERMINATED Phase PHASE2
NCT00135330 An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Status COMPLETED Phase PHASE3